QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International
Under the agreement, Proteomics International has the right to use the markers to develop and commercialize a blood-based early detection test for esophageal cancer.
Proteomics International Inks Israeli Distribution Deal for Diabetic Kidney Disease Immunoassay
The firm signed a deal with Zotal to be exclusive Israeli distributor of the test, which measures proteins in patient blood to detect diabetic kidney disease.
Proteomics International Inks Italian Distribution Deal for Diabetic Kidney Disease Immunoassay
The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.
Proteomics International Presents Study Data Supporting PromarkerD Kidney Disease Test
An analysis of 3,000 subjects found the test could identify diabetes patients at risk of developing chronic kidney disease within the next four years.
Proteomics International Kidney Disease Software Tool CE Marked
CE marking of PromarkerD Hub complements the CE mark that the mass spectrometry version of the test received in November.